-
Tips for becoming a good boxer - November 6, 2020
-
7 expert tips for making your hens night a memorable one - November 6, 2020
-
5 reasons to host your Christmas party on a cruise boat - November 6, 2020
-
What to do when you’re charged with a crime - November 6, 2020
-
Should you get one or multiple dogs? Here’s all you need to know - November 3, 2020
-
A Guide: How to Build Your Very Own Magic Mirror - February 14, 2019
-
Our Top Inspirational Baseball Stars - November 24, 2018
-
Five Tech Tools That Will Help You Turn Your Blog into a Business - November 24, 2018
-
How to Indulge on Vacation without Expanding Your Waist - November 9, 2018
-
5 Strategies for Businesses to Appeal to Today’s Increasingly Mobile-Crazed Customers - November 9, 2018
Lilly,Sanofi Enter Into Settlement Agreement In US Insulin Glargine Litigation
Separately, Sanofi confirmed that it has reached a settlement agreement with Eli Lilly and Company, which addresses patents on Sanofi’s Lantus SoloSTAR (insulin glargine).
Advertisement
The settlement relates to patents covering Sanofi’s Lantus SoloSTAR formulation of the basal insulin, a pen injector version which accounts for nearly two-thirds of Lantus $7bn total sales.
The US Food and Drug Administration tentatively approved Basaglar in August 2014.
Lantus is Sanofi’s best-selling product, with more than $7 billion in 2014 sales, so it’s no surprise that the company has been fighting back against Lilly and Boehringer Ingelheim’s biosimilar version.
Lilly and Boehringer already sell Basaglar in the Kwikpen in several European countries.
In addition, as part of the settlement, Lilly will pay Sanofi royalties in exchange for a license for certain patents.
Advertisement
Basaglar was granted tentative approval by the FDA previous year but its launch was delayed by a legal challenge for Sanofi which alleged infringement of four patents on Lantus. “Sanofi and Lilly accepted end that in fact court action and cut off comparable gainsays world-wide”. Lilly also sells the new diabetes pill Jardiance, recently shown in a study to prevent fatal heart attacks and strokes. Type 1 diabetes, often called insulin-dependent diabetes, typically is diagnosed in childhood or adolescence, while Type 2 diabetes typically strikes in middle age.